A larger prospective study with strict enrolment criteria is imperative to confirm these preliminary but valuable findings that were provided in our study and to further evaluate the safety and quality of life of LCT in PD-1/PD-L1 inhibitors-treated NSCLC patients with ORD. This evidence concerns the gene CD274 and non-small cell lung carcinoma.